Insider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells 20,000 Shares of Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRNGet Rating) CEO Jean Jacques Bienaime sold 20,000 shares of the business’s stock in a transaction on Thursday, April 28th. The stock was sold at an average price of $83.79, for a total transaction of $1,675,800.00. Following the transaction, the chief executive officer now directly owns 334,983 shares of the company’s stock, valued at approximately $28,068,225.57. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Monday, April 18th, Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $81.91, for a total transaction of $1,638,200.00.
  • On Thursday, April 14th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $83.66, for a total transaction of $836,600.00.
  • On Thursday, March 10th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $77.57, for a total transaction of $1,163,550.00.

Shares of BMRN stock opened at $83.31 on Tuesday. BioMarin Pharmaceutical Inc. has a 1 year low of $71.59 and a 1 year high of $94.20. The firm’s 50 day moving average is $79.97 and its 200-day moving average is $83.47. The firm has a market capitalization of $15.40 billion, a price-to-earnings ratio of 462.83, a PEG ratio of 1.81 and a beta of 0.49. The company has a current ratio of 4.21, a quick ratio of 2.77 and a debt-to-equity ratio of 0.25.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Rating) last announced its earnings results on Wednesday, April 27th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.48. BioMarin Pharmaceutical had a net margin of 2.09% and a return on equity of 1.37%. During the same quarter last year, the business earned $0.29 EPS. On average, equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 0.93 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Strs Ohio lifted its position in shares of BioMarin Pharmaceutical by 0.6% during the fourth quarter. Strs Ohio now owns 20,584 shares of the biotechnology company’s stock worth $1,818,000 after purchasing an additional 132 shares in the last quarter. Spire Wealth Management lifted its position in shares of BioMarin Pharmaceutical by 59.7% during the fourth quarter. Spire Wealth Management now owns 377 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 141 shares in the last quarter. CKW Financial Group lifted its position in shares of BioMarin Pharmaceutical by 23.1% during the first quarter. CKW Financial Group now owns 800 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 150 shares in the last quarter. Veriti Management LLC lifted its holdings in BioMarin Pharmaceutical by 4.0% in the fourth quarter. Veriti Management LLC now owns 3,981 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 153 shares during the period. Finally, Bbva USA lifted its holdings in BioMarin Pharmaceutical by 20.5% in the third quarter. Bbva USA now owns 934 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 159 shares during the period. Institutional investors own 95.45% of the company’s stock.

Several research firms have recently issued reports on BMRN. Truist Financial boosted their price objective on shares of BioMarin Pharmaceutical from $125.00 to $135.00 in a report on Monday, January 10th. StockNews.com assumed coverage on shares of BioMarin Pharmaceutical in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Piper Sandler upped their target price on shares of BioMarin Pharmaceutical from $121.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, February 24th. Wedbush lowered their target price on shares of BioMarin Pharmaceutical from $155.00 to $147.00 in a research note on Thursday, April 28th. Finally, Morgan Stanley raised shares of BioMarin Pharmaceutical from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $96.00 to $113.00 in a research note on Monday, April 25th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, BioMarin Pharmaceutical presently has a consensus rating of “Buy” and an average price target of $112.79.

BioMarin Pharmaceutical Company Profile (Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

See Also

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.